What question did this study set out to answer?

April 15, 2026Annals of HematologyOpen Access

Treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with multiple myeloma: longer follow-up of the real-world MMY4032 study

View Full Paper

Ask AI

Bookmark

Authors

WYWei YangChina Medical University LWLuqun WANG YWYafei WangTianjin Medical University Cancer Institute and Hospital

Discussion

Member takes

Implication

This observational study evaluates treatment patterns and efficacy of daratumumab in Chinese multiple myeloma patients, suggesting a standard of care approach.

Key Points

To assess the treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with multiple myeloma over a longer follow-up period.
Conducted a multicenter, noninterventional, observational study with a focus on real-world data.
Analyzed data from patients with multiple myeloma who received daratumumab over a median follow-up of 16.2 months.
Calculated treatment response rates, survival rates, and adverse events among patients treated with daratumumab.
Overall response rate increased to 74.1%, with 55.6% achieving very good partial response or better.
Median progression-free survival was 32.8 months, with high 12-month survival rates of 77.9% overall.
Adverse drug reactions were reported in 20.3% of patients, with serious adverse events in 15.6%.

Cite This Study

Yang et al. (2026) studied this question.

synapsesocial.com/papers/69df2a99e4eeef8a2a6af96c https://doi.org/10.1007/s00277-026-06972-8

View Full Paper

Ask AI

Bookmark

Implication

This observational study evaluates treatment patterns and efficacy of daratumumab in Chinese multiple myeloma patients, suggesting a standard of care approach.

Treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with multiple myeloma: longer follow-up of the real-world MMY4032 study

Discussion

Member takes

Implication

Key Points

Cite This Study

Treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with multiple myeloma: longer follow-up of the real-world MMY4032 study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider